Showing results (891-900 of 927) with videos related to
Sort By:
Pageof 93
Emerging Microbes & Infections|February 15, 2021
Inflammation-related adverse reactions following vaccination potentially indicate a stronger immune responseChun-Lan Zhuang, Zhi-Jie Lin, Zhao-Feng Bi, et al.Free Radical Biology & Medicine|January 18, 2021
Redox sensor NPGPx restrains ZAP70 activity and modulates T cell homeostasisFang-Yi Su, Shih-Chia Huang, Pei-Chi Wei, et al.Journal of Thoracic Disease|June 16, 2023
Nutritional status in patients with active pulmonary tuberculosis and new nutritional risk screening model for active tuberculosis: a national, multicenter, cross-sectional study in ChinaWei Chen, Qin Ding, Sheng-Kang Zhang, et al.Vaccine|June 24, 2015
Immunogenicity and safety of an E. coli-produced bivalent human papillomavirus (type 16 and 18) vaccine: A randomized controlled phase 2 clinical trialTing Wu, Yue-Mei Hu, Juan Li, et al.Lancet (London, England)|March 31, 2015
Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trialFeng-Cai Zhu, Li-Hua Hou, Jing-Xin Li, et al.International Journal of Cancer|April 18, 2014
Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18-25 years: results from a randomized controlled trialFeng-Cai Zhu, Wen Chen, Yue-Mei Hu, et al.Iscience|October 7, 2022
Multiomic characterization and drug testing establish circulating tumor cells as an <i>ex vivo</i> tool for personalized medicineJia-Yang Chen, Hsu-Huan Chou, Syer Choon Lim, et al.Vaccine|August 5, 2022
Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine (Sinopharm BBIBP-CorV) coadministered with quadrivalent split-virion inactivated influenza vaccine and 23-valent pneumococcal polysaccharide vaccine in China: A multicentre, non-inferiority, open-label, randomised, controlled, phase 4 trialHaiping Chen, Zhuoying Huang, Shaoying Chang, et al.Lancet (London, England)|December 27, 2016
Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trialFeng-Cai Zhu, Alie H Wurie, Li-Hua Hou, et al.Vaccine|April 27, 2022
Evaluation of a recombinant five-antigen Staphylococcus aureus vaccine: The randomized, single-centre phase 1a/1b clinical trialsFeng-Cai Zhu, Hao Zeng, Jing-Xin Li, et al.Pageof 93